What is BridgeBio Oncology Therapeutics Inc.'s Shariah compliance score?

BridgeBio Oncology Therapeutics Inc.'s (BBOT) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does BridgeBio Oncology Therapeutics Inc. pass AAOIFI screening?

BridgeBio Oncology Therapeutics Inc. (BBOT) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (BBOT: 0.4%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for BridgeBio Oncology Therapeutics Inc. stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for BridgeBio Oncology Therapeutics Inc. (BBOT) using the latest financial data.

Where can I screen BridgeBio Oncology Therapeutics Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for BridgeBio Oncology Therapeutics Inc. (BBOT) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about BBOT's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

BBOT: Is BridgeBio Oncology Therapeutics Inc. Halal?

BridgeBio Oncology Therapeutics Inc.

NASDAQHealthcareUS

$8.82

+0.23%

Market Cap: 706.5M

Compliance Status

Not Halal

Screened on Sep 2, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is BridgeBio Oncology Therapeutics Inc. (BBOT) halal? Not Halal. Based on AAOIFI screening, BridgeBio Oncology Therapeutics Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates BridgeBio Oncology Therapeutics Inc. (BBOT) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Sep 2, 2026. Source: https://halalscreener.app/en/stock/BBOT

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

0.4% of 30.0% limit

What this means for you

Most scholars advise not holding BBOT

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 2, 2026

Compliance History

Not Halalnow
since Aug 2026
Under Review
until the change above
Not Halal
until the change above

Tracked since Jun 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

RGCA+

Regencell Bioscience Holdings Limited

$5.02

-4.92%

0001.KLA+

Supercomnet Technologies Bhd

$0.49

-0.03%

0002.KLA+

Kotra Industries Bhd

$3.78

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.44

+0.01%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.37

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track BBOT and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is BridgeBio Oncology Therapeutics Inc. (BBOT) halal to invest in?

BridgeBio Oncology Therapeutics Inc. (BBOT) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did BridgeBio Oncology Therapeutics Inc. get a F compliance rating?

BridgeBio Oncology Therapeutics Inc. (BBOT) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.4% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change BridgeBio Oncology Therapeutics Inc.'s Shariah verdict?

BridgeBio Oncology Therapeutics Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is BridgeBio Oncology Therapeutics Inc. re-screened for Shariah compliance?

BridgeBio Oncology Therapeutics Inc. (BBOT) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 2, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.